Work Out for Free: Use facilities in the full fitness center (ages 13 and over), including basketball courts, indoor pool, track, pickleball, racquetball, steam room and sauna. -- Group Exercise ...

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.09%, and the Nasdaq ...

The S&P 500 Index ($SPX) (SPY) today is up +0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.08%, and the ...

The Chinese tariffs are set to take effect on February 10, potentially leaving room for negotiation ... 15% for a -25 bp rate cut at the next FOMC meeting on March 18-19. Overseas stock markets ...

The Chinese tariffs are set to take effect on February 10, potentially leaving room for negotiation ... 14% for a -25 bp rate cut at the next FOMC meeting on March 18-19. Overseas stock markets ...

Please note this conference is being recorded and for the ... AstraZeneca, Moderna, Regeneron, [Novacap] and Bayer, which I will elaborate on shortly. Additionally, I think we signed several ...

Welcome to the Q4 and Full Year 2024 Conference Call for Investors and ... And if our hypothesis or the fact that there is room for actually a better tolerable COVID-19 vaccine is indeed confirmed ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

Thank you for your interest in Regeneron , and welcome to our fourth quarter 2024 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...